Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882032 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05882032 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT05882032, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Interventions
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05882032
The ClinicalTrials.gov registry entry for NCT05882032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3502970 is the first listed.
NCT05882032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05882032 about?
NCT05882032 is a clinical study titled "A Study of LY3502970 in Participants With Impaired and Normal Liver Function". The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY350...
What is the current status of trial NCT05882032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-06-13. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT05882032?
The interventions under investigation include: LY3502970 (DRUG).
Who is sponsoring clinical trial NCT05882032?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.